Literature DB >> 15770016

Serotype incidence and antibiotic susceptibility of Streptococcus pneumoniae causing invasive disease in Scotland, 1999-2002.

B C Denham1, S C Clarke1.   

Abstract

Pneumococcal disease remains an important cause of invasive and non-invasive disease in Scotland and elsewhere. The Scottish Meningococcus and Pneumococcus Reference Laboratory receives isolates of Streptococcus pneumoniae from diagnostic laboratories around Scotland. Here, the serogroups/types and antibiotic-susceptibility patterns of invasive isolates received between 1999 and 2002 are described. There were a total of 1741 invasive isolates received, the most common serogroups/types being 14 (19.8 %), 9 (10.2 %), 6 (8.3 %), 19 (7.9 %), 23 (7.9 %), 4 (6.5 %), 8 (6.4 %), 3 (5.7 %), 1 (3.8 %), 7 (3.8 %) and 18 (3.4 %). Importantly, serotypes 7 and 8 are not represented in the 7-, 9- and 11-valent pneumococcal conjugate polysaccharide vaccines. There were 67 (3.8 %) isolates considered penicillin non-susceptible, although no penicillin resistance (MIC > or = 0.002 mg ml(-1)) was recorded. One hundred and ninety-four (11.1 %) isolates, predominantly of serotype 14, were resistant to erythromycin, and 12 (0.7 %) were resistant to ciprofloxacin. This information provides an important dataset that will prove essential prior to and during the implementation of pneumococcal conjugate vaccines in the UK.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15770016     DOI: 10.1099/jmm.0.45718-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  9 in total

1.  Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin.

Authors:  Lea-Ann S Kirkham; Johanna M C Jefferies; Alison R Kerr; Yu Jing; Stuart C Clarke; Andrew Smith; Tim J Mitchell
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Genomic diversity between strains of the same serotype and multilocus sequence type among pneumococcal clinical isolates.

Authors:  Nuno A Silva; Jackie McCluskey; Johanna M C Jefferies; Jason Hinds; Andrew Smith; Stuart C Clarke; Tim J Mitchell; Gavin K Paterson
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

3.  Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland.

Authors:  Stuart C Clarke; Johanna M Jefferies; Andrew J Smith; Jim McMenamin; Timothy J Mitchell; Giles F S Edwards
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

Review 4.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

5.  Acute exercise enhancement of pneumococcal vaccination response: a randomised controlled trial of weaker and stronger immune response.

Authors:  Kate M Edwards; Meredith A Pung; Lianne M Tomfohr; Michael G Ziegler; John P Campbell; Mark T Drayson; Paul J Mills
Journal:  Vaccine       Date:  2012-08-22       Impact factor: 3.641

6.  Invasive pneumococcal disease in New Zealand 1998-2005: capsular serotypes and antimicrobial resistance.

Authors:  H M Heffernan; D R Martin; R E Woodhouse; J Morgan; T K Blackmore
Journal:  Epidemiol Infect       Date:  2007-05-17       Impact factor: 2.451

7.  Dynamics of serotype 14 Streptococcus pneumoniae population causing acute respiratory infections among children in China (1997-2012).

Authors:  Mingming He; Kaihu Yao; Wei Shi; Wei Gao; Lin Yuan; Sangjie Yu; Yonghong Yang
Journal:  BMC Infect Dis       Date:  2015-07-11       Impact factor: 3.090

8.  Time of day of vaccination does not relate to antibody response to thymus-independent vaccinations.

Authors:  Anna C Whittaker; Stephen Gallagher; Mark Drayson
Journal:  Vaccine X       Date:  2022-06-13

9.  Serotypes and patterns of antibiotic resistance in strains causing invasive pneumococcal disease in children less than 5 years of age.

Authors:  Chunfeng Liu; Xiaoyu Xiong; Wei Xu; Jimei Sun; Lijie Wang; Jiujun Li
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.